In which patients with atypical HUS would you consider eculizumab discontinuation?

My approach to eculizumab cessation in aHUS is to at least consider cessation in all patients not only given the high cost of the drug, but also given the risk of meningococcemia, which is incompletely protected against by vaccines.

In treating aHUS, I initiate eculizumab (and preventive therapy for ...

I agree with all the points made by Dr. @Dr. First Last, but would add that genetic information can be useful in informing the discussion. Fakhouri et al recently published prospective data of 55 patients who discontinued eculizumab, 51% of which had complement gene rare variants. Overall, 23% exper...